232 related articles for article (PubMed ID: 33905019)
1. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Fujii Y; Kamachi H; Matsuzawa F; Mizukami T; Kobayashi N; Fukai M; Taketomi A
Invest New Drugs; 2021 Oct; 39(5):1256-1266. PubMed ID: 33905019
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
3. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model.
Mizukami T; Kamachi H; Fujii Y; Matsuzawa F; Einama T; Kawamata F; Kobayashi N; Hatanaka Y; Taketomi A
Oncotarget; 2018 Sep; 9(73):33844-33852. PubMed ID: 30333914
[TBL] [Abstract][Full Text] [Related]
4. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
5. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
7. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
8. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
9. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
Ogura Y; Mizumoto K; Nagai E; Murakami M; Inadome N; Saimura M; Matsumoto K; Nakamura T; Maemondo M; Nukiwa T; Tanaka M
Cancer Gene Ther; 2006 May; 13(5):520-9. PubMed ID: 16341142
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
[TBL] [Abstract][Full Text] [Related]
11. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
[TBL] [Abstract][Full Text] [Related]
12. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
Lindenberg L; Thomas A; Adler S; Mena E; Kurdziel K; Maltzman J; Wallin B; Hoffman K; Pastan I; Paik CH; Choyke P; Hassan R
Oncotarget; 2015 Feb; 6(6):4496-504. PubMed ID: 25756664
[TBL] [Abstract][Full Text] [Related]
13. Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
Prasad S; Yadav VR; Sung B; Gupta SC; Tyagi AK; Aggarwal BB
Oncotarget; 2016 Mar; 7(11):13182-96. PubMed ID: 26909608
[TBL] [Abstract][Full Text] [Related]
14. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
Zhao M; Tominaga Y; Ohuchida K; Mizumoto K; Cui L; Kozono S; Fujita H; Maeyama R; Toma H; Tanaka M
Cancer Sci; 2012 Jan; 103(1):58-66. PubMed ID: 21954965
[TBL] [Abstract][Full Text] [Related]
15. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
[TBL] [Abstract][Full Text] [Related]
16. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
[TBL] [Abstract][Full Text] [Related]
17. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
18. Dihomo-γ-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.
Yang X; Xu Y; Gao D; Yang L; Qian SY
Redox Biol; 2019 Jan; 20():236-246. PubMed ID: 30384258
[TBL] [Abstract][Full Text] [Related]
19. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
[TBL] [Abstract][Full Text] [Related]
20.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
